Xenon Pharmaceuticals (XENE) Stock Forecast, Price & News

Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions

Is Xenon Pharmaceuticals a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Xenon Pharmaceuticals stock.
View analyst ratings for Xenon Pharmaceuticals or view top-rated stocks.

When is Xenon Pharmaceuticals' next earnings date?

Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Xenon Pharmaceuticals.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) announced its quarterly earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.03. Xenon Pharmaceuticals had a negative trailing twelve-month return on equity of 20.94% and a negative net margin of 360.80%. During the same period last year, the firm earned ($0.42) EPS.
View Xenon Pharmaceuticals' earnings history.

What price target have analysts set for XENE?

6 equities research analysts have issued 12-month target prices for Xenon Pharmaceuticals' shares. Their forecasts range from $40.00 to $48.00. On average, they expect Xenon Pharmaceuticals' share price to reach $44.00 in the next year. This suggests a possible upside of 51.0% from the stock's current price.
View analysts' price targets for Xenon Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Xenon Pharmaceuticals' key executives?

Xenon Pharmaceuticals' management team includes the following people:

• Dr. Simon N. Pimstone FRCPC, M.B. ChB., M.D., Ph.D., Exec. Chairman (Age 54, Pay $787.78k)
• Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA, Pres, CEO & Director (Age 46, Pay $667.55k)
• Ms. Sherry Aulin, Chief Financial Officer (Age 38)
• Ms. Jodi Regts M.B.A., B.A., MBA, VP of Corp. Affairs & Investor Relations
• Ms. Shelley McCloskey B.A., Sr. VP of HR (Age 62)
• Dr. Robin P. Sherrington, Exec. VP of Strategy & Innovation (Age 61)
• Dr. James R. Empfield Ph.D., Exec. VP of Drug Discovery (Age 61)
• Ms. Sheila M. Grant M.B.A., M.Sc., MBA, Sr. VP of R&D Operations
• Dr. Christopher E. Von Seggern M.B.A., M.P.H., Ph.D., M.P.H. M.B.A, Chief Commercial Officer (Age 43)
• Dr. Kenneth Sommerville, Interim Chief Medical Officer

Who are some of Xenon Pharmaceuticals' key competitors?

Some companies that are related to Xenon Pharmaceuticals include Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Intra-Cellular Therapies (ITCI), Ascendis Pharma A/S (ASND), Acerus Pharmaceuticals (ASPCF), Hypera (HYPMY), Perrigo (PRGO), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Galapagos (GLPG), Cerevel Therapeutics (CERE), Zai Lab (ZLAB) and Bausch Health Companies (BHC).
View all of XENE's competitors.

What other stocks do shareholders of Xenon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx), Sangamo Therapeutics (SGMO), Arbutus Biopharma (ABUS), OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI).

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Polar Capital Holdings Plc (4.12%), Lord Abbett & CO. LLC (3.37%), Great Point Partners LLC (1.73%), Capital International Investors (1.63%), Rock Springs Capital Management LP (1.59%) and Goldman Sachs Group Inc. (1.36%). Company insiders that own Xenon Pharmaceuticals stock include Christopher John Kenney, Frank A Holler, James R Empfield, Seggern Christopher Von, Sherrington Robin and Simon N Pimstone.
View institutional ownership trends for Xenon Pharmaceuticals.

Which institutional investors are selling Xenon Pharmaceuticals stock?

XENE stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Bank of New York Mellon Corp, Capital International Investors, Kynam Capital Management LP, Invesco Ltd., Affinity Asset Advisors LLC, Parkman Healthcare Partners LLC, and Great Point Partners LLC. Company insiders that have sold Xenon Pharmaceuticals company stock in the last year include Frank A Holler, James R Empfield, Sherrington Robin, and Simon N Pimstone.
View insider buying and selling activity for Xenon Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Xenon Pharmaceuticals stock?

XENE stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Polar Capital Holdings Plc, Eversept Partners LP, CI Investments Inc., Citigroup Inc., Walleye Capital LLC, Candriam Luxembourg S.C.A., and Rock Springs Capital Management LP. Company insiders that have bought Xenon Pharmaceuticals stock in the last two years include Christopher John Kenney, and Seggern Christopher Von.
View insider buying and selling activity for Xenon Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $29.14.

How much money does Xenon Pharmaceuticals make?

Xenon Pharmaceuticals has a market capitalization of $1.55 billion and generates $18.44 million in revenue each year. The biopharmaceutical company earns $-78.88 million in net income (profit) each year or ($1.79) on an earnings per share basis.

How many employees does Xenon Pharmaceuticals have?

Xenon Pharmaceuticals employs 149 workers across the globe.

What is Xenon Pharmaceuticals' official website?

The official website for Xenon Pharmaceuticals is www.xenon-pharma.com.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at [email protected], or via fax at 604-484-3450.